China Approves the World's First CAR-T Cell Therapy for Solid Tumors

Claudin18.2 is a tight-junction protein that is commonly overexpressed on the surface of gastric, GEJ, and pancreatic cancer cells but is minimally expressed in normal tissues. This makes it an attractive target for a therapy designed to kill tumor cells while largely sparing healthy cells .

The approved indication is for:

• Claudin18.2-positive advanced gastric or gastroesophageal junction adenocarcinoma
• in patients who have failed at least two prior lines of systemic therapy

The pivotal Phase II trial (CT041-ST-01)

The clinical basis for the approval was the Phase II CT041-ST-01 trial (NCT04581473), an open-label, multicenter, randomized study. It enrolled 156 patients with CLDN18.2-positive advanced G/GEJ cancer who had already received at least two prior treatments . The results were published in The Lancet and presented at the 2025 ASCO Annual Meeting .

The trial met its primary endpoint: satri-cel significantly prolonged progression-free survival compared to standard therapy, with a hazard ratio of 0.37, meaning a 63% reduction in the risk of disease progression or death at the time of analysis . Overall survival also showed a clinically meaningful improvement .

Regulatory pathway: A fast track to approval

Satri-cel moved through the Chinese regulatory system on an accelerated timeline:

• September 2020 – U.S. FDA granted Orphan Drug Designation for gastric/GEJ cancer .
• January 2022 – U.S. FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation .
• March 2025 – China's NMPA granted Breakthrough Therapy Designation (BTD) .
• May 28, 2025 – NMPA granted Priority Review status .
• Late June 2025 – NMPA formally accepted the New Drug Application (NDA) for review .
• June 22, 2026 – NMPA approval .

What this means for cell therapy and for China

Satri-cel's approval is not just a milestone for a single drug. It has broader implications:

1. Proving CAR-T can work in solid tumors. Until now, CAR-T had been spectacularly effective in hematologic malignancies but had largely failed in solid tumors, which have a hostile tumor microenvironment. Satri-cel demonstrates that with the right molecular target (Claudin18.2) and optimized CAR design, durable responses in solid tumors are achievable .

2. Cementing China's leadership in cell therapy. China now has 6–8 NMPA-approved CAR-T products covering hematologic indications, and satri-cel is the first to break into solid tumors . China has the world's most active CAR-T clinical pipeline and manufacturing costs that are approximately 30–60% of U.S. pricing, making it a global hub for cell therapy development .

3. Opening a regulatory path for other solid tumor CAR-Ts. This approval sets a regulatory precedent in China that paves the way for other solid tumor candidates targeting mesothelin, GPC3, EGFR, and other antigens .

Important caveats

While the approval is historic, it is limited to China. Satri-cel has not yet received U.S. FDA or European Medicines Agency (EMA) approval. The FDA has granted it Orphan Drug and RMAT designations, but a global Phase III or bridging trial may still be required for U.S. marketing authorization . In addition, the long-term survival data remains early, and real-world durability will need to be confirmed as patients are followed post-approval.

The bottom line

Satri-cel is the first CAR-T cell therapy approved for any solid tumor — an achievement that represents a genuine scientific and regulatory milestone. For the millions of patients with advanced gastric cancer worldwide who have exhausted standard options, it offers a new, mechanistically distinct approach. And for the field of cell therapy, it proves that the solid tumor barrier can finally be breached.